Melanoma in immunosuppressed patients

References

• Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer77, 1303–1310 (1996).
   PubMed Web of Science ®Google Scholar
• Halliday GM, Patel A, Hunt MJ, Tefany FJ, Barnetson RS. Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells. World J. Surg.19, 352–358 (1995).
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Eliyahu S, Delgado CH et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl Acad. Sci. USA91, 3515–3519 (1994).
   PubMed Web of Science ®Google Scholar
• Marshall JA, Forster TH, Purdie DM et al. Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma. Immunol. Cell. Biol.84, 295–302 (2006).
   PubMed Web of Science ®Google Scholar
• Menzies SW, McCarthy WH. Complete regression of primary cutaneous malignant melanoma. Arch. Surg.132, 553–556 (1997).
   PubMedGoogle Scholar
• Belloni-Fortina A, Piaserico S, Tonin E, Alaibac M. Melanoma and immunosuppression. Dermatology218, 88; author reply 89 (2009).
   PubMed Web of Science ®Google Scholar
• Baumgartner J, Wilson C, Palmer B, Richter D, Banerjee A, McCarter M. Melanoma induces immunosuppression by up-regulating FOXP3+ regulatory T cells. J. Surg. Res.141, 72–77 (2007).
   PubMed Web of Science ®Google Scholar
• Javia LR, Rosenberg SA. CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J. Immunother.26, 85–93 (2003).
   PubMed Web of Science ®Google Scholar
• Viguier M, Lemaitre F, Verola O et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol.173, 1444–1453 (2004).
   PubMed Web of Science ®Google Scholar
• Polak ME, Borthwick NJ, Gabriel FG et al. Mechanisms of local immunosuppression in cutaneous melanoma. Br. J. Cancer96, 1879–1887 (2007).
   PubMed Web of Science ®Google Scholar
• Chen Q, Daniel V, Maher DW, Hersey P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int. J. Cancer56, 755–760 (1994).
   PubMed Web of Science ®Google Scholar
• Brandacher G, Perathoner A, Ladurner R et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res.12, 1144–1151 (2006).
   PubMed Web of Science ®Google Scholar
• Harlin H, Kuna TV, Peterson AC, Meng Y, Gajewski TF. Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites. Cancer Immunol. Immunother.55, 1185–1197 (2006).
   PubMed Web of Science ®Google Scholar
• Ritter MR, Moreno SK, Dorrell MI et al. Identifying potential regulators of infantile hemangioma progression through large-scale expression analysis: a possible role for the immune system and indoleamine 2,3 dioxygenase (IDO) during involution. Lymphat. Res. Biol.1, 291–299 (2003).
   PubMedGoogle Scholar
• Cochran AJ, Wen DR, Farzad Z et al. Immunosuppression by melanoma cells as a factor in the generation of metastatic disease. Anticancer Res.9, 859–864 (1989).
   PubMed Web of Science ®Google Scholar
• Wilson LJ, Horvat RT, Tilzer L, Meis AM, Montag L, Huntrakoon M. Identification of donor melanoma in a renal transplant recipient. Diagn. Mol. Pathol.1, 266–271 (1992).
   PubMedGoogle Scholar
• Jensen P, Hansen S, Moller B et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J. Am. Acad. Dermatol.40, 177–186 (1999).
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am. J. Transplant.4, 905–913 (2004).
   PubMed Web of Science ®Google Scholar
• Le Mire L, Hollowood K, Gray D, Bordea C, Wojnarowska F. Melanomas in renal transplant recipients. Br. J. Dermatol.154, 472–477 (2006).
   PubMed Web of Science ®Google Scholar
• Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br. J. Dermatol.143, 513–519 (2000).
   PubMed Web of Science ®Google Scholar
• Penn I. Malignant melanoma in organ allograft recipients. Transplantation61, 274–278 (1996).
   PubMed Web of Science ®Google Scholar
• Hollenbeak CS, Todd MM, Billingsley EM, Harper G, Dyer AM, Lengerich EJ. Increased incidence of melanoma in renal transplantation recipients. Cancer104, 1962–1967 (2005).
   PubMed Web of Science ®Google Scholar
• Alaibac M, Piaserico S, Rossi CR et al. Eruptive melanocytic nevi in patients with renal allografts: report of 10 cases with dermoscopic findings. J. Am. Acad. Dermatol.49, 1020–1022 (2003).
   PubMed Web of Science ®Google Scholar
• Bouwes Bavinck JN, Crijns M, Vermeer BJ et al. Chronic sun exposure and age are inversely associated with nevi in adult renal transplant recipients. J. Invest. Dermatol.106, 1036–1041 (1996).
   PubMed Web of Science ®Google Scholar
• Barker JN, MacDonald DM. Eruptive dysplastic naevi following renal transplantation. Clin. Exp. Dermatol.13, 123–125 (1988).
   PubMed Web of Science ®Google Scholar
• McGregor JM, Barker JN, MacDonald DM. The development of excess numbers of melanocytic naevi in an immunosuppressed identical twin. Clin. Exp. Dermatol.16, 131–132 (1991).
   PubMed Web of Science ®Google Scholar
• Gulec AT, Seckin D, Saray Y, Sarifakioglu E, Moray G, Colak T. Number of acquired melanocytic nevi in renal transplant recipients as a risk factor for melanoma. Transplant. Proc.34, 2136–2138 (2002).
   PubMed Web of Science ®Google Scholar
• Grob JJ, Bastuji-Garin S, Vaillant L et al. Excess of nevi related to immunodeficiency: a study in HIV-infected patients and renal transplant recipients. J. Invest. Dermatol.107, 694–697 (1996).
   PubMed Web of Science ®Google Scholar
• Szepietowski J, Wasik F, Szepietowski T, Wlodarczyk M, Sobczak-Radwan K, Czyz W. Excess benign melanocytic naevi in renal transplant recipients. Dermatology194, 17–19 (1997).
   PubMed Web of Science ®Google Scholar
• Laing ME, Moloney FJ, Comber H, Conlon P, Murphy GM. Malignant melanoma in renal transplant recipients. Br. J. Dermatol.155, 857 (2006).
   PubMed Web of Science ®Google Scholar
• Laing ME, Moloney FJ, Kay EW, Conlon P, Murphy GM. Malignant melanoma in transplant patients: review of five cases. Clin. Exp. Dermatol.31, 662–664 (2006).
   PubMed Web of Science ®Google Scholar
• Cuchural GJ Jr, Levey AS, Pauker SG. Kidney failure or cancer. Should immunosuppression be continued in a transplant patient with malignant melanoma? Med. Decis. Making4, 82–107 (1984).
   PubMed Web of Science ®Google Scholar
• Hodi FS, Granter S, Antin J. Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case report. Cancer Immun.5, 7 (2005).
   PubMedGoogle Scholar
• Matin RN, Mesher D, Proby CM et al. Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases. Am. J. Transplant.8, 1891–1900 (2008).
   PubMed Web of Science ®Google Scholar
• Dapprich DC, Weenig RH, Rohlinger AL et al. Outcomes of melanoma in recipients of solid organ transplant. J. Am. Acad. Dermatol.59, 405–417 (2008).
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wen S, McLaughlin P et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J. Clin. Oncol.27, 904–910 (2009).
   PubMed Web of Science ®Google Scholar
• Adami J, Frisch M, Yuen J, Glimelius B, Melbye M. Evidence of an association between non-Hodgkin’s lymphoma and skin cancer. BMJ310, 1491–1495 (1995).
   PubMed Web of Science ®Google Scholar
• McKenna DB, Doherty VR, McLaren KM, Hunter JA. Malignant melanoma and lymphoproliferative malignancy: is there a shared aetiology? Br. J. Dermatol.143, 171–173 (2000).
   PubMed Web of Science ®Google Scholar
• McKenna DB, Stockton D, Brewster DH, Doherty VR. Evidence for an association between cutaneous malignant melanoma and lymphoid malignancy: a population-based retrospective cohort study in Scotland. Br. J. Cancer88, 74–78 (2003).
   PubMed Web of Science ®Google Scholar
• Travis LB, Curtis RE, Hankey BF, Fraumeni JF Jr. Second cancers in patients with chronic lymphocytic leukemia. J. Natl Cancer Inst.84, 1422–1427 (1992).
   PubMed Web of Science ®Google Scholar
• Brewer JD, Christenson LJ, Weenig RH, Weaver AL. Effects of chronic lymphocytic leukemia on the development and progression of malignant melanoma. Dermatol. Surg.36(3), 368–376 (2010).
   PubMed Web of Science ®Google Scholar
• Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit. Rev. Clin. Lab. Sci.43, 1–67 (2006).
   PubMed Web of Science ®Google Scholar
• Hamai A, Richon C, Meslin F et al. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: relationship to Bcl-2 family and caspase activation. Oncogene25, 7618–7634 (2006).
   PubMed Web of Science ®Google Scholar
• Mikhail M, Velazquez E, Shapiro R et al. PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin. Cancer Res.11, 5153–5157 (2005).
   PubMed Web of Science ®Google Scholar
• Coll-Mulet L, Gil J. Genetic alterations in chronic lymphocytic leukaemia. Clin. Transl. Oncol.11, 194–198 (2009).
   PubMed Web of Science ®Google Scholar
• Gahn B, Schafer C, Neef J et al. Detection of trisomy 12 and Rb-deletion in CD34+ cells of patients with B-cell chronic lymphocytic leukemia. Blood89, 4275–4281 (1997).
   PubMed Web of Science ®Google Scholar
• Colegio OR, Proby CM, Bordeaux JS, McGregor JM. Prognosis of pretransplant melanoma. Am. J. Transplant.9, 862 (2009).
   PubMed Web of Science ®Google Scholar